

**AMENDMENTS TO THE SPECIFICATION**

**Please delete the paragraph bridging pages 114-115.**

**Please amend the paragraphs added on page 115, by amendment of March 8, 2004, as follows:**

~~Fig 8A and B~~ Figs. 7A and B show TPO given to healthy donors: Results of TPO clinical trials from recent research on healthy platelet donors, as compared to our computer simulation results. (A) Comparison of experimental data from the literature (~~dots~~ dotted line) and our model simulation (solid line without dots). In both cases, TPO was given as a single IV dose of 1.2 µg/kg on day 0. (B) Comparison of the same experimental data (~~dots~~ dotted line) and our proposed TPO administration protocol; the total dose in the simulated protocol was 0.3 µg/kg (solid line without dots).

~~Figs. 9A and B~~ 8A and B show TPO with chemotherapy: (A) Results of clinical trials from recent research on thrombocytopenia induced in patients receiving single carboplatin chemotherapy on day 0 (dots connected by a continuous line), as compared to our model simulation of these results (continuous solid line without dots). (B) The same experimental data (dots connected by a continuous line) compared to simulations of the same chemotherapy protocol, with addition of “conventional” TPO as a single IV dose of 1.2 µg/kg on day 0 (continuous solid line without dots) and simulations of the same chemotherapy protocol combined with our proposed TPO protocol, using a total of 0.3 µg/kg TPO (dotted line).